Fernando Ferrero, Chien-Yu Lin, Johannes Liese, Kleber Luz, Tatyana Stoeva, Agnes Nemeth, Manuel Gijón, Cristina Calvo, Silvina Natalini, Teck-Hock Toh, Sofie Deleu, Bohang Chen, Sarah Rusch, Beatriz López Sánchez, Illse Leipoldt, Leen Vijgen, Dymphy Huntjens, Tristan Baguet, Kristi Bertzos, Mohamed Gamil, Marita Stevens
BACKGROUND: Respiratory syncytial virus (RSV) causes significant morbidity and mortality in children aged ≤ 5 years and adults aged ≥ 60 years worldwide. Despite this, RSV-specific therapeutic options are limited. Rilematovir is an investigational, orally administered inhibitor of RSV fusion protein-mediated viral entry. OBJECTIVE: To establish the antiviral activity, clinical outcomes, safety, and tolerability of rilematovir (low or high dose) in children aged ≥ 28 days and ≤ 3 years with RSV disease...
April 22, 2024: Paediatric Drugs